Advances in mRNA-Based Melanoma Vaccines: A Narrative Review of Lipid Nanoparticle and Dendritic Cell Delivery Platforms
Cells · 2026
DOI: 10.3390/cells15020099 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2026. Verfasst von Connor K Sisk und 3 weiteren Autor:innen. Beteiligte Einrichtung: Heersink School of Medicine, University of Alabama at Birmingham, 1670 University Blvd, Birmingham, AL 35294, USA. Hauptthemen laut MEDLINE: Dendritic Cells, Cancer Vaccines, Melanoma, Nanoparticles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Melanoma remains one of the deadliest cutaneous malignancies worldwide, and despite advances in systemic therapy, recurrence and treatment resistance remain frequent challenges. Following the success of COVID-19 mRNA vaccines, mRNA-based cancer vaccines targeting melanoma antigens have emerged as a promising therapeutic direction. This review summarizes current evidence on mRNA melanoma vaccines, focusing on two leading delivery platforms: lipid nanoparticles (LNPs) and dendritic cell (DC) vaccines. A comprehensive search of MEDLINE, Embase, and Scopus from 2015 to 2025 identified clinical trials, preclinical studies, and review articles evaluating mRNA vaccine constructs and delivery strategies. Completed clinical studies demonstrate that personalized LNP-formulated mRNA vaccines can enhance neoantigen-specific T-cell responses and improve recurrence-free survival, particularly when combined with immune checkpoint inhibitors. DC-based mRNA vaccines also show potent immunogenicity, with stronger responses observed when DC maturation is optimized. Ongoing trials continue to investigate next-generation LNP formulations, DC priming strategies, and personalized neoantigen approaches. Overall, current evidence indicates that both LNP and DC platforms can augment antitumor immunity by broadening T-cell responses and enhancing checkpoint inhibition. Continued refinement of delivery vehicles, neoantigen selection, and scalable manufacturing processes will be essential to realizing the full clinical potential of mRNA vaccines in melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Heersink School of Medicine, University of Alabama at Birmingham, 1670 University Blvd, Birmingham, AL 35294, USA.
- Department of Dermatology, University of Alabama at Birmingham, 1670 University Blvd, VH566A, Birmingham, AL 35294, USA.
ORCID-Profile: Connor K Sisk, Laci M Turner, Shafkat Meraj, Nabiha Yusuf
Zitieren
APA
Sisk, C. K., Turner, L. M., Meraj, S., & Yusuf, N. (2026). Advances in mRNA-Based Melanoma Vaccines: A Narrative Review of Lipid Nanoparticle and Dendritic Cell Delivery Platforms. Cells. https://doi.org/10.3390/cells15020099
Vancouver
Sisk CK, Turner LM, Meraj S, Yusuf N. Advances in mRNA-Based Melanoma Vaccines: A Narrative Review of Lipid Nanoparticle and Dendritic Cell Delivery Platforms. Cells. 2026. doi:10.3390/cells15020099
BibTeX
@article{Sisk2026,
author = {Sisk, Connor K and Turner, Laci M and Meraj, Shafkat and Yusuf, Nabiha},
title = {Advances in mRNA-Based Melanoma Vaccines: A Narrative Review of Lipid Nanoparticle and Dendritic Cell Delivery Platforms},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15020099}
}
EUVIMED